We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ananda Developments Plc | AQSE:ANA | Aquis Stock Exchange | Ordinary Share | GB00BDQPXQ60 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.50 | 0.40 | 0.65 | 0.58 | 0.475 | 0.50 | 5,257,684 | 15:29:44 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMANA
RNS Number : 1527Z
Ananda Developments PLC
15 May 2023
12 May 2023
ANANDA DEVELOPMENTS PLC
("Ananda" or the "Company")
Appointment of AQSE Corporate Adviser and Broker
Following the completion of the acquisition of MRX Global Limited and its wholly owned subsidiary MRX Medical Limited and raising of GBP427,400, the directors of Ananda are pleased to announce that SP Angel Corporate Finance LLP ("SP Angel") has been appointed as the Company's AQSE Corporate Adviser and sole Broker, with immediate effect.
SP Angel has a dedicated in-house healthcare research team and will release an Initiation Research Report on the Company in the coming weeks. As SP Angel acts as a NOMAD it would be able to support Ananda with a smooth transition to AIM at the appropriate time.
Ananda's CEO, Melissa Sturgess, commented: "Ananda's ambition to be a provider of cannabis-based medicines for the treatment of complex, chronic inflammatory pain conditions, places us firmly in the healthcare sector. We believe that working with the dedicated, experienced, and respected healthcare research and capital markets team at SP Angel will help us refine our story, expand our reach to a wider audience and prepare the company for bigger markets. I would also like to take this opportunity, on behalf of the Board, to thank Peterhouse for its support and guidance as our corporate adviser and broker since Ananda's listing in 2018."
-Ends-
The Directors of the Company accept responsibility for the contents of this announcement.
ANANDA DEVELOPMENTS PLC +44 (0)7463 686 497 ir@anandadevelopments.com Chief Executive Officer Melissa Sturgess Chief Operating Officer Jeremy Sturgess-Smith SP ANGEL CORPORATE FINANCE LLP +44 (0)20 3470 0470 Corporate Finance Richard Morrison Harry Davies-Ball Corporate Broking Abigail Wayne Rob Rees
About Ananda Developments
Ananda is an AQSE-listed medical cannabis company whose ambition is to be a leading provider of high-quality medical cannabis for the treatment of complex, chronic inflammatory pain conditions for the UK and international markets.
For more information, please visit: https://anandadevelopments.com/
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NEXMZGMKDMFGFZM
(END) Dow Jones Newswires
May 15, 2023 02:00 ET (06:00 GMT)
1 Year Ananda Developments Chart |
1 Month Ananda Developments Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions